Roche Introduces Automated Test for Hepatitis D Virus
The fully automated, high-throughput assay for Hepatitis D virus RNA is available on cobas 5800/6800/8800 systems in CE mark-accepting countries.
The fully automated, high-throughput assay for Hepatitis D virus RNA is available on cobas 5800/6800/8800 systems in CE mark-accepting countries.
The NCCN has updated its bladder cancer guidelines to include FDA-approved ctDNA-based MRD testing for post-surgical risk assessment and adjuvant immunotherapy decisions in muscle-invasive bladder cancer.
New updates include expanded capabilities for microbial identification and advancements in sepsis diagnostics and sequencing workflows.
New clinical utility data showed that offering a blood-based lung cancer test increased screening participation compared with low-dose CT screening alone.
Read MoreThe panel detects fungal DNA in plasma to help identify specific pathogens in immunocompromised patients.
Read MoreMonitoring circulating tumor DNA dynamics outperformed standard markers for predicting survival and relapse in early-stage patients.
Read MoreThe study demonstrated that patients who test positive for ctDNA “actually benefit from chemotherapy.”
Read MoreResearch shows optical genome mapping identifies genomic changes in nearly 98% of T-cell acute lymphoblastic leukemia cases compared to 55% with traditional analysis.
Read MoreResults from the NHS-Galleri study show a 26% reduction in metastatic cancer diagnoses by the third round of screening.
Read MoreThe test uses a new approach to identify signs of cancer recurrence with faster result times for healthcare providers and patients.
Read MoreThe new 3B-NEO service uses whole exome and whole genome sequencing to identify risks for serious childhood-onset disorders before symptoms appear.
Read MoreClinical results show high sensitivity for colorectal cancer relapse and ultra-low detection limits for lung cancer.
Read MoreResults from the PATHFINDER 2 trial show the Galleri test identifies 6.5 times more cancers when used with standard screenings.
Read MoreUpdated criteria integrate clinical manifestations and genetic testing to reduce the time required to reach an informed diagnosis.
Read MoreThe integrated electrophoresis solution is designed to simplify routine verification by eliminating gel casting and buffer preparation.
Read MoreThe multicenter study will evaluate proactive outreach to at-risk relatives and the impact of multigene panel testing on patient care.
Read MoreThe Callisto Sample Prep System application is optimized for the PromethION platform to support whole genome sequencing workflows.
Read MoreThe settlement follows a criminal conviction and addresses more than $174 million in fraudulent Medicare claims involving multiple laboratories.
Read More